Acaltrol IV Injection contains Calcitriol. Acaltrol IV Injection is used for:
Acaltrol IV Injection is indicated for the correction of the abnormalities of Calcium and Phosphate metabolism in patients with renal osteodystrophy.
Acaltrol IV Injection is also indicated for the treatment of established post-menopausal osteoporosis, hypoparathyroidism, idiopathic hypoparathyroidism, pseudohypoparathyroidism, vitamin D dependent rickets.
Acaltrol IV Injection is one of the most important active metabolites of vitamin D3. It is normally formed in the kidney from its precursor, 25-hydroxycolecalciferol (25-HCC). Physiological daily production is normally 0.5-1.0 mcg and is somewhat higher during periods of increased bone synthesis (e.g. growth or pregnancy). Acaltrol IV Injection promotes intestinal absorption of Calcium and regulates bone mineralization.
Vitamin in bone formation, Vitamin-D preparations
The recommended intravenous initial dose of Acaltrol IV Injection injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals.
Renal osteodystrophy: The initial daily dose is 0.25 mcg of Acaltrol IV Injection. In patients with normal or only slighty reduced Calcium level, doses of 0.25 mcg every other day are sufficient. If no satisfactory response in the biochemical parameters and clinical manifestations of the disease is observed within 2-4 weeks, the daily dosage may be increased by 0.25 mcg at 2-4 week intervals.
Post-menopausal osteoporosis: The recommended dose of Acaltrol IV Injection is 0.25 mcg twice daily.
Serum calcium and creatinin levels should be determined at 1-3 and 6 months and at 6 monthly intervals thereafter.
Hypoparathyroidism & Rickets: The recommended initial dose of Acaltrol IV Injection is 0.25 mcg per day in the morning. In patients with renal osteodystrophy or hypoparathyroidism and rickets if within 2-4 weeks no satisfactory response is observed by usual dose then dose may be increased at two to four week intervals.
No specific dosage modifications are required in elderly patents.
Dosage in children has not been established.
Since Acaltrol IV Injection exerts vitamin D activity, adverse effects may occur which are similar to those found when an excessive dose of vitamin D is taken, i.e. hypercalcaemia syndrome or calcium intoxication (depending on the severity and duration of hypercalcaemia). Occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation.
Immobilised patients, e.g. those who have undergone surgery, are particularly exposed to the risk of hypercalcaemia. Patients with normal renal function who are taking Acaltrol IV Injection should avoid dehydration. Adequate fluid intake should be maintained.
Concomitant treatment with a thiazide diuretic increases the risk of hypercalcaemia. Acaltrol IV Injection dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcaemia in such patients may precipitate cardiac arrhythmias. Administration of enzyme inducers such as phenytoin or phenobarbital may lead to increased metabolism and hence reduced serum concentrations of Acaltrol IV Injection. Therefore higher doses of Acaltrol IV Injection may be necessary if these drugs are administered simultaneously. Colestyramine can reduce intestinal absorption of fat-soluble vitamins and therefore may impair intestinal absorption of Acaltrol IV Injection.
Pregnancy category C. Acaltrol IV Injection has been found to be teratogenic in rabbits. There are no adequate and well-controlled studies in pregnant women. Acaltrol IV Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Administration of Acaltrol IV Injection to patients in excess of their daily requirements can cause hypercalcaemia, hypercalciuria and hyperphospatemia. Since Acaltrol IV Injection is a derivative of vitamin D, the signs and symptoms of overdose are the same as for an overdose of vitamin D.
Acaltrol IV Injection is contraindicated in patients with known hypersensitivity to any of its ingredients. Acaltrol IV Injection is also contraindicated in all diseases associated with hypercalcemia.
Store between 15-30° C. Protect from moisture, heat and light. Do not freeze.
Elderly patients: No specific dosage modifications are required in elderly patients.
Acaltrol IV Injection price in Bangladesh 0